Brief: Sirnaomics Announces Interim Data From Phase I Clinical Trial Of Rnai Therapeutic Stp707 For Treatment Of Multiple Solid Tumors
20/12/2022 17:49
Dec 20 (Reuters) - Sirnaomics Ltd 2257.HK :
* SIRNAOMICS ANNOUNCES INTERIM DATA FROM PHASE I CLINICAL
TRIAL OF
RNAI THERAPEUTIC STP707 FOR TREATMENT OF MULTIPLE SOLID TUMORS
* SIRNAOMICS LTD - FIRST THREE OUT OF FIVE COHORTS PASS
SAFETY
REQUIREMENTS
* SIRNAOMICS LTD - ANTICIPATE DOSING FOURTH COHORT IN Q1
2023
* SIRNAOMICS LTD- TO DATE, STP707 HAS EXHIBITED A STRONG
SAFETY
PROFILE WHEN COMPARED TO OTHER NOVEL ONCOLOGY THERAPEUTICS
Source text for Eikon: ID:nPn6CDw3Da
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million